S9562Temporary National Codes (Non-Medicare)
Home injectable therapy, palivizumab or other monoclonal antibody for rsv,
Short description: Ht inj palivizumab/ab diem
- Effective date
- April 1, 2023
- Termination date
- —
Related codes (S-series)
S0012Butorphanol tartrate, nasalS0013Esketamine, nasal sprayS0014Tacrine hydrochloride, 10 mgS0017Injection, aminocaproic acidS0020Injection, bupivicaine hydroS0021Injection, cefoperazone sodS0023Injection, cimetidine hydrocS0028Injection, famotidine, 20 mgS0030Injection, metronidazoleS0032Injection, nafcillin sodiumS0034Injection, ofloxacin, 400 mgS0039Injection, sulfamethoxazole
Frequently asked questions
What is HCPCS code S9562?
S9562 is a HCPCS Level II code for Home injectable therapy, palivizumab or other monoclonal antibody for rsv,.
What category is HCPCS code S9562 in?
S9562 falls under the Temporary National Codes (Non-Medicare) category of HCPCS Level II.
When did HCPCS code S9562 become effective?
S9562 has been effective since April 1, 2023, per CMS's quarterly HCPCS update.
HCPCS Level II data from CMS (public domain). HCPCS Level I (CPT) codes are not included — CPT is copyrighted by the American Medical Association. Always verify codes with authoritative sources before making coding or billing decisions.